drugset / Trial / NCT01907217

Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression

NCT01907217

RandomizedParallel-groupTriple-blindTreatment

Summary

Electroconvulsive therapy (ECT) is the most powerful antidepressant treatment available and is often life-saving. There are concerns, however, that standard bitemporal ECT (the most commonly used form of ECT worldwide) causes persisting retrograde amnesia. However, clinical trials have indicated that high-dose unilateral ECT may be as effective as bitemporal ECT but have much less cognitive side-effects. The trial aims to test the primary experimental hypothesis: High-dose (6 x ST) right unilateral ECT is as effective as (i.e. not inferior to) standard (1.5 x ST) bitemporal ECT for severe depression in terms of Hamilton Depression Rating Score (HDRS) at the end of the treatment course.

Timeline

Start
2008-05
Primary completion
2013-11
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Background Methohexital Small molecule 0.75 mg/kg
Background Methohexital Small molecule 1 mg/kg
Background Suxamethonium Other / unclassified 0.5 mg/kg
Background Suxamethonium Other / unclassified 1 mg/kg

Indications